- seekingalpha.com
- Posted On 08 November 2026
Vir Biotechnology reports positive hepatitis results, early signs of possible cure (VIR:NASDAQ)
Vir plans to seek FDA approval in mid-2027 and expects additional Eclipse 2 and Eclipse 3 results in the first quarter of 2027. Breakthrough therapy and fast tr...
Source:
seekingalpha.com